NASDAQ:ENTA Enanta Pharmaceuticals - ENTA News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $39.60 -0.09 (-0.23%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$38.86▼$40.4550-Day Range$39.60▼$54.5952-Week Range$37.59▼$79.50Volume172,108 shsAverage Volume177,520 shsMarket Capitalization$827.09 millionP/E RatioN/ADividend YieldN/APrice Target$68.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Media Mentions By Week ENTA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTA News Sentiment▼-0.180.35▲Average Medical News Sentiment ENTA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTA Articles This Week▼112▲ENTA Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHennion & Walsh Asset Management Inc. Lowers Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)marketbeat.com - March 23 at 5:18 AMEnanta Pharmaceuticals' (ENTA) "Sector Perform" Rating Reaffirmed at Royal Bank of Canadaamericanbankingnews.com - March 23 at 5:40 AMExpert Ratings for Enanta Pharmamarkets.businessinsider.com - March 22 at 7:53 PMInsider Selling: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) VP Sells $618,966.25 in Stockamericanbankingnews.com - March 20 at 5:06 AMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $68.60 Consensus Price Target from Brokeragesamericanbankingnews.com - March 20 at 2:02 AMInsider Selling: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Sells $1,260,505.92 in Stockamericanbankingnews.com - March 17 at 4:38 AMEnanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Researchfinance.yahoo.com - March 8 at 7:21 PMEnanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conferencefinance.yahoo.com - March 7 at 10:08 AMEnanta Pharmaceuticals First Quarter 2023 Earnings: Beats Expectationsfinance.yahoo.com - February 9 at 3:17 PMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Call Transcriptfinance.yahoo.com - February 8 at 6:48 PMThese Analysts Just Made A Huge Downgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) EPS Forecastsfinance.yahoo.com - February 8 at 1:47 PMEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ETfinance.yahoo.com - February 7 at 5:16 PMEnanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conferencefinance.yahoo.com - February 7 at 7:15 AMEnanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022finance.yahoo.com - January 31 at 8:33 AMEnanta Pharmaceuticals (ENTA) Shares Cross Above 200 DMAnasdaq.com - January 24 at 9:07 PMSVB Securities Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)markets.businessinsider.com - January 16 at 10:05 AMAnalysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Enanta Pharmaceuticals (ENTA) and Day One Biopharmaceuticals (DAWN)markets.businessinsider.com - January 10 at 1:01 PMAn Intrinsic Calculation For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Suggests It's 49% Undervaluedfinance.yahoo.com - January 6 at 9:00 AMEnanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 6 at 9:00 AMEnanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 10:25 AMEnanta: Deep Losses In FY 2022 Look To Be Justified Given Macro Landscapeseekingalpha.com - December 30 at 1:34 PMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - December 25 at 1:44 PMNewsflash: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Analysts Have Been Trimming Their Revenue Forecastsfinance.yahoo.com - November 23 at 6:52 AMEnanta Pharmaceuticals to Participate in Two Investor Conferences in Novemberfinance.yahoo.com - November 22 at 10:36 AMEnanta Pharmaceuticals, Inc. (ENTA) Q4 2022 Earnings Call Transcriptseekingalpha.com - November 21 at 9:14 PMEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ETfinance.yahoo.com - November 21 at 4:13 PMEarnings Outlook For Enanta Pharmaceuticalsbenzinga.com - November 18 at 10:42 AMEnanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022finance.yahoo.com - November 14 at 10:53 AMEnanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19finance.yahoo.com - November 9 at 7:22 AMInvestors in Enanta Pharmaceuticals (NASDAQ:ENTA) have unfortunately lost 51% over the last yearfinance.yahoo.com - November 3 at 2:54 PMEnanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022finance.yahoo.com - October 19 at 9:56 AMEnanta Pharmaceuticals, Inc. (ENTA)finance.yahoo.com - October 17 at 5:31 PMEnanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virusfinance.yahoo.com - October 17 at 9:22 AMEnanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virusfinance.yahoo.com - October 3 at 7:53 AMEnanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposiumfinance.yahoo.com - September 29 at 11:14 AMEnanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposiumfinance.yahoo.com - September 22 at 10:23 AMNew Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022finance.yahoo.com - September 7 at 11:32 AMEnanta Pharmaceuticals to Participate in Two Investor Conferences in Septemberfinance.yahoo.com - September 1 at 7:31 AMNeed To Know: Analysts Just Made A Substantial Cut To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimatesfinance.yahoo.com - August 14 at 6:51 PMThe Petri Dish: Cyteir puts a drug on pause, Alexion vet joins Watertown biotechfinance.yahoo.com - August 11 at 5:49 PMEnanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?nasdaq.com - August 9 at 8:18 PMEnanta Pharmaceuticals (ENTA) Q3 2022 Earnings Call Transcriptfinance.yahoo.com - August 9 at 2:47 AMEnanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2022 Results - Earnings Call Transcriptseekingalpha.com - August 8 at 9:41 PMEnanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimatesfinance.yahoo.com - August 8 at 9:41 PMEnanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officerfinance.yahoo.com - August 8 at 4:40 PMEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ETfinance.yahoo.com - August 8 at 4:40 PMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Brokeragesamericanbankingnews.com - August 4 at 1:12 AMBullish Two Hundred Day Moving Average Cross - ENTAnasdaq.com - August 3 at 8:24 PMWhat 13 Analyst Ratings Have To Say About Enanta Pharmaceuticalsmarkets.businessinsider.com - August 1 at 7:10 PMEnanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022finance.yahoo.com - August 1 at 8:07 AMEnanta Shares Rise On Positive Data From Initial-Stage Covid Studymarkets.businessinsider.com - July 29 at 3:31 PM Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:ENTA) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.